{
    "clinical_study": {
        "@rank": "97518", 
        "acronym": "FluTBI", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Other", 
            "description": "Fludarabine, Total Body Irradiation (TBI)"
        }, 
        "brief_summary": {
            "textblock": "The goal of this research is to test if the conditioning regimen, fludarabine and total body\n      irradiation (FluTBI), can lead to a safer and more effective stem cell transplant treatment\n      regimen for ALL patients older than 40 years of age and/or younger patients with high risk\n      medical conditions. The primary objective is to establish the efficacy of allo HCT in older\n      ALL using myeloablative FluTBI conditioning regimen. ZThe investigators are also assessing\n      the safety and toxicity of allo HCT in older ALL using myeloablative FluTBI conditioning\n      regimen."
        }, 
        "brief_title": "Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia", 
        "condition": "Adult Lymphoblastic Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Disease Criteria:\n\n               -  ALL in complete remission (CR) at the time of transplant. Remission is defined\n                  as \"less than 5.0% bone marrow lymphoblasts by morphology,\" as determined by a\n                  bone marrow aspirate obtained within 2 weeks of study registration.\n\n               -  Philadelphia chromosome positive ALL is allowed.\n\n               -  Lymphoid blastic crisis of CML will be included (provided that patients achieve\n                  CR).\n\n          -  Age Criteria: Equal or above age 40 and up to 65 years. If younger than 40, there\n             must be comorbidities which preclude the patient to undergo CyTBI conditioning\n             regimen.\n\n          -  Organ Function Criteria: All organ function testing should be done within 28 days of\n             study registration.\n\n          -  Cardiac: Left ventricular ejection fraction (LVEF) \u2265 50% by MUGA (Multi Gated\n             Acquisition) scan or echocardiogram.\n\n          -  Pulmonary: FEV1 (Forced expiratory volume in 1 second) and FVC (Forced vital\n             capacity) \u2265 50% predicted, DLCO (alveolar diffusion capacity for carbon monoxide)\n             (corrected for hemoglobin) \u2265 50% of predicted.\n\n          -  Renal: The estimated creatinine clearance (CrCl) must be equal or greater than 60\n             mL/min/1.73 m2 as calculated by the Cockcroft-Gault Formula:\n\n        CrCl = (140-age) x weight (kg) x 0.85 (if female)/72 x serum creatinine (mg/dL).\n\n          -  Hepatic:\n\n               -  Serum bilirubin 2.0 g/dL\n\n               -  Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN\n\n               -  Alkaline phosphatase 2.5 ULN\n\n          -  Performance status: Karnofsky \u2265 70%\n\n          -  Consent: Patient must be informed of the investigational nature of this study in\n             accordance with institutional and federal guidelines and have the ability to provide\n             written informed consent prior to initiation of any study-related procedures, and\n             ability,in the opinion of the principal investigator, to comply with all the\n             requirements of the study.\n\n          -  Presence of a willing adult HLA-matched sibling (excluding identical twin) or\n             HLA-matched unrelated donor meeting all the criteria for routine allo HSCT. All\n             donors will be evaluated for eligibility and suitability per the standard of care\n             according to the FACT and NMDP guidelines.\n\n        Exclusion Criteria:\n\n          -  Non-compliant to medications.\n\n          -  No appropriate caregivers identified.\n\n          -  HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive\n\n          -  Active life-threatening cancer requiring treatment other than ALL\n\n          -  Uncontrolled medical or psychiatric disorders.\n\n          -  Uncontrolled infections, defined as positive blood cultures within 72 hours of study\n             entry, or evidence of progressive infection by imaging studies such as chest CT scan\n             within 14 days of registration.\n\n          -  Active central nervous system (CNS) leukemia\n\n          -  Preceding allogeneic HSCT\n\n          -  Receiving intensive chemotherapy within 21 days of registration. Maintenance type of\n             chemotherapy will be allowed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991457", 
            "org_study_id": "UAB 1285"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "Fludarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "Total Body Irradiation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fludarabine", 
                "Fludarabine monophosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "ALL", 
        "lastchanged_date": "November 17, 2013", 
        "location": {
            "contact": {
                "email": "liwilliams@uabmc.edu", 
                "last_name": "Lisa D Williams, RN, RN", 
                "phone": "205-934-0066"
            }, 
            "contact_backup": {
                "email": "andrewdees@uamc.edu", 
                "last_name": "Andrew T Dees", 
                "phone": "205-975-7665"
            }, 
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35249"
                }, 
                "name": "UAB Bone Marrow Transplantation and Cellular Therapy Program"
            }, 
            "investigator": [
                {
                    "last_name": "Ayman A Saad, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Shin Mineishi, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Donna Salzman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Racquel D Innis-Shelton, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ruby Meredith, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lawrence S Lamb, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "William Donnellan, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen", 
        "overall_contact": {
            "email": "liwilliams@uabmc.edu", 
            "last_name": "Lisa D Williams, RN", 
            "phone": "205-934-0066"
        }, 
        "overall_contact_backup": {
            "email": "andrewdees@uabmc.edu", 
            "last_name": "Andrew T Dees", 
            "phone": "205-975-7665"
        }, 
        "overall_official": {
            "affiliation": "University of Alabama at Birmingham", 
            "last_name": "Ayman A Saad, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects Disease-free survival", 
            "safety_issue": "No", 
            "time_frame": "2 years post-transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991457"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects that survived", 
                "safety_issue": "No", 
                "time_frame": "2 years post-transplant"
            }, 
            {
                "description": "Neutrophil engraftment is defined as the first of 3 consecutive days with an absolute neutrophil count (ANC) > 500/\u03bcL.", 
                "measure": "Number of subjects with neutrophil engraftment", 
                "safety_issue": "No", 
                "time_frame": "Within the first 100 days"
            }, 
            {
                "measure": "Number of subjects with regimen related toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Within first 100 days post-transplant"
            }, 
            {
                "measure": "Number of subjects with Acute GVHD", 
                "safety_issue": "No", 
                "time_frame": "2 years post transplant"
            }, 
            {
                "description": "Track the growth rate of and the number of lymphocyte subsets.", 
                "measure": "Mean rate of Immune Reconstitution", 
                "safety_issue": "No", 
                "time_frame": "1 year post transplant"
            }, 
            {
                "measure": "Number of subjects with relapse", 
                "safety_issue": "No", 
                "time_frame": "2 Years post-transplant"
            }, 
            {
                "description": "Platelet engraftment is defined as the first of 3 consecutive days with a platelet count > 20,000/\u03bcL without platelet transfusion for 7 days.", 
                "measure": "Number of subjects with platelet engraftment", 
                "safety_issue": "Yes", 
                "time_frame": "Within 100 days post transplant"
            }, 
            {
                "measure": "Number of subjects with chronic GVHD", 
                "safety_issue": "No", 
                "time_frame": "2 years post transplant"
            }
        ], 
        "source": "University of Alabama at Birmingham", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}